{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:22:02Z","timestamp":1648840922583},"reference-count":9,"publisher":"Informa Healthcare","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1517\/13543784.12.10.1709","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T16:42:57Z","timestamp":1115224977000},"page":"1709-1712","source":"Crossref","is-referenced-by-count":0,"title":["Is there a role for oral blockade of platelet glycoprotein IIb\/IIIa receptors in coronary and cerebrovascular disease?"],"prefix":"10.1517","volume":"12","author":[{"given":"Amar M","family":"Salam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"CIT0001","first-page":"399","volume":"108","author":"TOPOL EJ","year":"2003","journal-title":"Blockade of the Glycoprotein IIb\/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Circulation"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.11.1645"},{"key":"CIT0005","first-page":"1316","volume":"342","author":"O'NEIL WW","year":"2000","journal-title":"Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: Excite Trial Investigators: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl. I Med."},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.2.149"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11179-6"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.13.1727"},{"key":"CIT0009","first-page":"201","volume":"103","author":"CHEW DP","year":"2001","journal-title":"A meta-analysis of Phase III multicenter randomized trials. Circulation"},{"key":"CIT0011","first-page":"728","volume":"102","author":"HARRINGTON RA","year":"2000","journal-title":"The Anti-Platelet Useful Dose (APLAUD) Study Investigators. Circulation"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.8.5760"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.12.10.1709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T08:01:00Z","timestamp":1481616060000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.12.10.1709"}},"subtitle":["TOPOL EJ, EASTON D, HARRINGTON RA et al.: Randomized, double-blind, placebo-controlled, international trial of the oral IIb\/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Blockade of the Glycoprotein IIb\/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Circulation (2003) 108(4):399-406."],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":9,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,3,2]]},"published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1517\/13543784.12.10.1709"],"URL":"https:\/\/doi.org\/10.1517\/13543784.12.10.1709","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}